PL422917A1 - Concentration of cadmium in full blood, connected with increased risk of malignant tumors in women who are carriers of BRCA1 gene mutation - Google Patents

Concentration of cadmium in full blood, connected with increased risk of malignant tumors in women who are carriers of BRCA1 gene mutation

Info

Publication number
PL422917A1
PL422917A1 PL422917A PL42291717A PL422917A1 PL 422917 A1 PL422917 A1 PL 422917A1 PL 422917 A PL422917 A PL 422917A PL 42291717 A PL42291717 A PL 42291717A PL 422917 A1 PL422917 A1 PL 422917A1
Authority
PL
Poland
Prior art keywords
cadmium
concentration
risk
women
carriers
Prior art date
Application number
PL422917A
Other languages
Polish (pl)
Other versions
PL237085B1 (en
Inventor
Wojciech MARCINIAK
Róża Derkacz
Jan LUBIŃSKI
Magdalena MUSZYŃSKA
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL422917A priority Critical patent/PL237085B1/en
Publication of PL422917A1 publication Critical patent/PL422917A1/en
Publication of PL237085B1 publication Critical patent/PL237085B1/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określania ryzyka zachorowania na raka, charakteryzuje się tym, że w próbce materiału biologicznego pobranej od pacjentki będącej nosicielką konstytucyjnej mutacji BRCA1 skorelowanej z podwyższonym ryzykiem raka, określa się zawartość kadmu, przy czym w przypadku pacjentki poniżej 51 roku życia: ryzyko zachorowania na raka uznaje się za znacząco podwyższone przy zawartości kadmu odpowiadającej wysokiemu stężeniu kadmu we krwi, zwłaszcza stężeniu powyżej 0,32 µg/l, ryzyko zachorowania na raka uznaje się za znacząco obniżone przy zawartości kadmu odpowiadającej obniżonemu stężeniu kadmu we krwi, zwłaszcza stężeniu poniżej 0,32 µg/l.The subject of the notification is a method for determining the risk of developing cancer, characterized by the fact that in a sample of biological material taken from a patient who is a carrier of the constitutional BRCA1 mutation correlated with an increased risk of cancer, the content of cadmium is determined, whereas in the case of a patient under 51 years of age: the risk of developing for cancer is considered to be significantly increased at a cadmium content corresponding to a high concentration of cadmium in the blood, especially a concentration above 0.32 µg / l, the risk of cancer is considered to be significantly reduced at a cadmium content corresponding to a reduced concentration of cadmium in the blood, especially a concentration below 0 , 32 µg / l.

PL422917A 2017-09-21 2017-09-21 Concentration of cadmium in full blood, connected with increased risk of malignant tumors in women who are carriers of BRCA1 gene mutation PL237085B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL422917A PL237085B1 (en) 2017-09-21 2017-09-21 Concentration of cadmium in full blood, connected with increased risk of malignant tumors in women who are carriers of BRCA1 gene mutation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL422917A PL237085B1 (en) 2017-09-21 2017-09-21 Concentration of cadmium in full blood, connected with increased risk of malignant tumors in women who are carriers of BRCA1 gene mutation

Publications (2)

Publication Number Publication Date
PL422917A1 true PL422917A1 (en) 2019-03-25
PL237085B1 PL237085B1 (en) 2021-03-08

Family

ID=65799934

Family Applications (1)

Application Number Title Priority Date Filing Date
PL422917A PL237085B1 (en) 2017-09-21 2017-09-21 Concentration of cadmium in full blood, connected with increased risk of malignant tumors in women who are carriers of BRCA1 gene mutation

Country Status (1)

Country Link
PL (1) PL237085B1 (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOTSOPOULOS, J. ET AL., PLASMA MICRONUTRIENTS, TRACE ELEMENTS AND BREAST CANCER IN BRCA1 MUTATION CARRIERS: AN EXPLORATORY STUDY, 2012 *
PENG, L. ET AL., CADMIUM EXPOSURE AND THE RISK OF BREAST CANCER IN CHAOSHAN POPULATION OF SOUTHEAST CHINA, 2015 *
WEI, Z. ET AL., CADMIUM PROMOTES THE PROLIFERATION OF TRIPLE-NEGATIVE BREAST CANCER CELLS THROUGH EGFR-MEDIATED CELI CYCLE REGULATION, 15 November 2015 (2015-11-15) *

Also Published As

Publication number Publication date
PL237085B1 (en) 2021-03-08

Similar Documents

Publication Publication Date Title
Liu et al. Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients
Harouaka et al. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications
Hopkins et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma
Jin et al. CD11b− CD27− NK cells are associated with the progression of lung carcinoma
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
MX2020005640A (en) Humanized anti-liv1 antibodies for the treatment of breast cancer.
Liang et al. LncRNA HOTAIR promotes proliferation, invasion and migration in NSCLC cells via the CCL22 signaling pathway
Tian et al. Association between dairy intake and gastric cancer: a meta-analysis of observational studies
Gao et al. Solanine inhibits immune escape mediated by hepatoma Treg cells via the tgfβ/smad signaling pathway
Tejero et al. Methylmalonic acid induces metabolic abnormalities and exhaustion in CD8+ T cells to suppress anti-tumor immunity
Grzanka et al. Correlation of SATB1 expression with clinical course of cutaneous T-cell lymphomas
Kroemer et al. STAT3 inhibition for cancer therapy: Cell-autonomous effects only?
PL422917A1 (en) Concentration of cadmium in full blood, connected with increased risk of malignant tumors in women who are carriers of BRCA1 gene mutation
Gipsyianti et al. High expression of COX-2 Associated with the depth of Invasion on Acral Melanoma by increasing TGF-β1
Hu et al. Tumor-infiltrating neutrophils predict poor outcome in adenocarcinoma of the esophagogastric junction
Long et al. HOXB7 predicts poor clinical outcome in patients with advanced esophageal squamous cell cancer
PL414266A1 (en) Concentration of selenium in blood as a risk factor for cancers in women
PL439315A1 (en) The method of determining the risk of cancer in women depending on the concentration of selenium in the blood
Dai et al. Tartrate-resistant acid phosphatase 5 regulates the metabolic flexibility of macrophages in the tumor microenvironment, thereby influencing their functional fate and modulating tumor growth
BR et al. Trends in oesophagus and Stomach cancer incidence in Bangalore, India.
PL415635A1 (en) Concentration of zinc in blood and changes within GPX1 gene, as risk factors for breast or ovary cancers in carriers of BRCA1 mutation, subjected to the uterine adnexa removal operation
PL415640A1 (en) Concentration of iron in blood and changes within HFE gene as risk factors for cancers in women
PL415632A1 (en) Concentration in blood and changes within IL6 gene as risk factors for cancers in women
PL415643A1 (en) Concentration of iron in blood and changes within GPX1 gene as risk factors for cancers in women
Dongliang et al. Expression of plasma miR-210, miR-378 and theirs clinical significance in renal clear cell carcinoma